Compare Johnson & Johnson (JNJ) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Vanguard Short Term Corporate Bond ETF — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Vanguard Short Term Corporate Bond ETF trades at $77.3 (market cap $51.90B). The key difference: Johnson & Johnson is far larger — about 11.9× Vanguard Short Term Corporate Bond ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while Vanguard Short Term Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Vanguard Short Term Corporate Bond ETF for 52 Days on average.
| JNJ | VCSH | |
|---|---|---|
Market Cap | $618.09B | $51.90B |
Volume | 6,050,983 | 2,892,221 |
Sector | Health | Fixed Income |
52-Week High | $278.43 | $80.20 |
52-Week Low | $186.00 | $77.03 |
Typical Hold Time | 129 Days | 52 Days |
Enterprise Value | $646.37B | — |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
VCSH trades at $77.30 with minimal daily movement (+0.04%). The technical picture shows a bearish trend with moving averages signaling caution, while oscillators remain neutral. Recent news highlights VCSH's competitive 4.5-4.8% dividend yield and low 0.03% expense ratio, though credit spreads remain tight. The ETF's short 2.7-year duration provides some protection against rising rates.
VCSH offers stable income exposure to investment-grade corporate bonds but faces headwinds from tight credit spreads and limited price appreciation potential. The fund's low duration minimizes interest rate risk, making it suitable for conservative investors seeking yield above Treasury alternatives, though corporate credit risk remains a consideration in economic downturns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
